M
Maze Therapeutics, Inc. (MAZE)
NGM – Real Time Price. Currency in USD
25.78
+0.26 (1.02%)
At close: May 12, 2026, 4:00 PM EDT
26.62
+0.84 (3.26%)
After-hours: May 12, 2026, 7:41 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
25.78
+0.26 (1.02%)
At close: May 12, 2026, 4:00 PM EDT
26.62
+0.84 (3.26%)
After-hours: May 12, 2026, 7:41 PM EDT
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research & Development and Chief Medical Officer |
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | CEO & Director |
| Mr. Atul Dandekar | Chief Strategy & Business Officer |
| Mr. Maarten Hoek | Senior Vice President of Research |
| Mr. Matt Krause | Senior Vice President of Human Resources |
| Mr. Misbah Tahir CPA | Chief Financial Officer |
| Mr. Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations |
| Ms. Amy Bachrodt | Senior Vice President of Finance |
| Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary |
| Ms. Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain |
| Date | Type | Document |
|---|---|---|
| 2026-04-28 | DEFA14A | ef20071648_defa14a.htm |
| 2026-04-28 | ARS | ef20071733_ars.pdf |
| 2026-04-22 | 8-K | d115741d8k.htm |
| 2026-03-25 | 10-K | maze-20251231.htm |
| 2026-02-04 | S-3ASR | d19492ds3asr.htm |
| 2025-10-17 | S-1 | d67735ds1.htm |
| 2025-10-06 | 8-K | d84372d8k.htm |
| 2025-09-11 | 8-K | d90404d8k.htm |
| 2025-09-02 | 8-K | d11864d8k.htm |
| 2025-08-12 | 8-K | maze-20250812.htm |